NEW YORK (GenomeWeb News) – CLC Bio will develop a bioinformatics platform for Aarhus University Hospital to support an interdisciplinary genomics study that seeks to develop new tools for predicting prostate cancer risk and aggressiveness.
The Danish company said today that it will develop a platform for analyzing microarray and next-generation sequencing data for the multi-partner study, which is funded with $4 million by the Danish Council for Strategic Research.
The aim of the project, led by Aarhus' department of molecular medicine, is to identify and validate new molecular markers for predicting prostate cancer aggressiveness and risk.
The project also will involve Aarhus University's Bioinformatics Research Centre and the Research Unit for General Medicine, the Norris Comprehensive Cancer Center at the University of Southern California, the department of pathology at the University of Erlangen-Nuremberg, and BGI.
CLC Bio's director of R&D, Roald Forsberg said in a statement that the company plans to develop "a user-friendly and comprehensive functional genomics platform for integrated analysis" of a range of biomarker types, including those based on copy number variations, methylation, mRNA, miNA, ncRNA, and others.
Aarhus University Hospital professr Torben Ørntoft said that new methods are needed to identify whether prostate cancer cases, which have increased in Denmark by nearly 8 percent per year for the past 10 years, are aggressive or non-aggressive, so that the right treatment plans can be provided quickly.